Xortx Therapeutics Inc. (XRTX) is a cutting-edge biotechnology company specializing in drug-based therapies for orphan diseases and kidney health. With a focus on aberrant purine metabolism and high serum uric acid imbalance, we aim to address conditions such as Autosomal Dominant Polycystic Kidney Disease, Coronavirus/COVID-19, and Type 2 Diabetic Nephropathy.

Our extensive portfolio includes patents and patent applications covering the development of uric acid-lowering agents for a range of conditions including hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury. Clinical and scientific evidence supports our innovative approach, showing that chronically elevated uric acid levels contribute to obesity, high blood pressure, inflammation, and progressive kidney and diabetes symptoms. Phase II studies have demonstrated the potential of our therapies to block weight gain, decrease blood pressure, and improve kidney function.

As we continue to evolve, we are also exploring treatments for acute organ injuries associated with COVID-19. Led by a team of kidney disease experts, we are dedicated to developing groundbreaking medications to enhance the lives of patients with progressive kidney failure